News

View all
Thumbnail image for Lilly shells out $960m on CoLucid

Lilly shells out $960m on CoLucid

Eli Lilly is buying US biopharma CoLucid in a deal worth around $960 million, in a move designed to boost its migraine pain management portfolio with a late-stage candidate offering a potential near-term market launch.

19th January 2017

Thumbnail image for Boehringer files Humira biosimilar in EU, US

Boehringer files Humira biosimilar in EU, US

Boehringer Ingeheim's biosimilar to AbbVie's mega blockbuster Humira has been accepted for review on both sides of the Atlantic, after having shown comparability in late-stage trials.

19th January 2017

Thumbnail image for UCB, Dermira plan psoriasis filing for Cimzia in Q3

UCB, Dermira plan psoriasis filing for Cimzia in Q3

UCB and Dermira are expecting to file anti-inflammatory Cimzia for psoriasis in the third quarter of this year, after the drug's strong performance in a late-stage trial involving patients with severe chronic plaque forms of the skin disease.

19th January 2017

Web Exclusives

View all
Thumbnail image for Thinking alike

Thinking alike

How can pharma help the NHS achieve Parity of Esteem in mental health?

Thumbnail image for Difficult breathing

Difficult breathing

Mesothelioma expert Dr Raja Flores on the state of treatment for this often neglected disease

Thumbnail image for A new way in

A new way in

The ins and out of the controversial proposed changes to NICE and its HST assessments

Webinars

View all

Designing Pharma organisations for success

Across all industries, people are changing the ways they engage with products, services, and brands. View more...

Wednesday, 28 September 2016 - 11:00 am
George Underwood
FREE - Listen again now - | VIEW NOW

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download